Skip to main navigation Skip to search Skip to main content

Nondisclosure of HIV status in a clinical trial setting: Antiretroviral drug screening can help distinguish between newly diagnosed and previously diagnosed HIV infection

  • Mark A. Marzinke
  • , William Clarke
  • , Lei Wang
  • , Vanessa Cummings
  • , Ting Yuan Liu
  • , Estelle Piwowar-Manning
  • , Autumn Breaud
  • , Sam Griffith
  • , Susan Buchbinder
  • , Steven Shoptaw
  • , Carlos Del Rio
  • , Manya Magnus
  • , Sharon Mannheimer
  • , Sheldon D. Fields
  • , Kenneth H. Mayer
  • , Darrell P. Wheeler
  • , Beryl A. Koblin
  • , Susan H. Eshleman
  • , Jessica M. Fogel

Research output: Contribution to journalArticlepeer-review

Abstract

In The HIV Prevention Trials Network 061 study, 155 human immunodeficiency virus (HIV)-infected men reported no prior HIV diagnosis; 83 of those men had HIV RNA levels of <1000 copies/mL at enrollment. Antiretroviral drug testing revealed that 65 of the 83 (78.3%) men were on antiretroviral treatment. Antiretroviral drug testing can help distinguish between newly diagnosed and previously diagnosed HIV infection.

Original languageEnglish (US)
Pages (from-to)117-120
Number of pages4
JournalClinical Infectious Diseases
Volume58
Issue number1
DOIs
StatePublished - Jan 1 2014

All Science Journal Classification (ASJC) codes

  • Microbiology (medical)
  • Infectious Diseases

Fingerprint

Dive into the research topics of 'Nondisclosure of HIV status in a clinical trial setting: Antiretroviral drug screening can help distinguish between newly diagnosed and previously diagnosed HIV infection'. Together they form a unique fingerprint.

Cite this